US7022330B2 - Parenteral formulation for epothilone analogs - Google Patents

Parenteral formulation for epothilone analogs Download PDF

Info

Publication number
US7022330B2
US7022330B2 US10/051,727 US5172702A US7022330B2 US 7022330 B2 US7022330 B2 US 7022330B2 US 5172702 A US5172702 A US 5172702A US 7022330 B2 US7022330 B2 US 7022330B2
Authority
US
United States
Prior art keywords
epothilone analog
mixture
solution
epothilone
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US10/051,727
Other languages
English (en)
Other versions
US20020143038A1 (en
Inventor
Rebanta Bandyopadhyay
Timothy M. Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R-PHARM US OPERATING LLC
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
US case filed in New Jersey District Court litigation Critical https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A12-cv-07800 Source: District Court Jurisdiction: New Jersey District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in New Jersey District Court litigation https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/1%3A13-cv-04171 Source: District Court Jurisdiction: New Jersey District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in New Jersey District Court litigation https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/1%3A12-cv-07800 Source: District Court Jurisdiction: New Jersey District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
First worldwide family litigation filed litigation https://patents.darts-ip.com/?family=23005123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7022330(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/051,727 priority Critical patent/US7022330B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VARIA, SAILESH AMILAL, RAGHAVAN, KRISHNASWAMY SRINIVAS, BANDYOPADHYAY, REBENTA, MALLOY, TIMOTHY M., PANAGGIO, ANDREA
Publication of US20020143038A1 publication Critical patent/US20020143038A1/en
Priority to US11/226,017 priority patent/US20060013836A1/en
Publication of US7022330B2 publication Critical patent/US7022330B2/en
Application granted granted Critical
Priority to US12/264,375 priority patent/US8632788B2/en
Priority to US14/134,172 priority patent/US20140107169A1/en
Priority to US14/686,005 priority patent/US20150218179A1/en
Assigned to R-PHARM US OPERATING LLC reassignment R-PHARM US OPERATING LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRISTOL-MYERS SQUIBB COMPANY
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an improved formulation for parenteral administration of certain epothilone analogs that are characterized by enhanced clinical efficacy.
  • Epothilones are macrolide compounds having utility in the pharmaceutical field.
  • Epothilones A and B having the structures:
  • TAXOL® paclitaxel
  • cytotoxic activity against rapidly proliferating cells such as, tumor cells or other hyperproliferative cellular disease, see Hofle et al., Angew. Chem. Int. Ed. Engl ., Vol. 35, No. 13/14, 1567–1569 (1996); WO 93/10121 published May 27, 1993; and WO 97/19086 published May 29, 1997.
  • Epothilones A and B have been synthesized and may be used to treat a variety of cancers and other abnormal proliferative diseases. Such analogs are disclosed in Hofle et al., Id.; Nicolaou et al., Angew Chem. Int. Ed. Engl ., Vol. 36, No. 19, 2097–2103 (1997); and Su et al., Angew Chem. Int. Ed. Engl ., Vol. 36, No. 19, 2093–2097 (1997).
  • the present invention describes a formulation and the preparation thereof for epothilone analogs represented by formula I.
  • the epothilone analog is initially solubilized with a mixture of tertiary-butanol and water and then lyophilized under optimized conditions.
  • the lyophilized drug is reconstituted first with a mixture of a polyethoxylated castor oil surfactant and anhydrous ethanol, and thereafter diluted with Lactated Ringer's Injection to a concentration appropriate for administration.
  • Q is selected from the group consisting of:
  • M is selected from the group consisting of oxygen, sulfur, NR 8 , and CR 9 R 10 ;
  • each R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 11 , R 12 , R 13 , R 14 and R 15 is, in independently, selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl and heterocyclo, and wherein R 1 and R 2 are alkyl, they can be joined to form cycloalkyl;
  • R 6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo and substituted heterocyclo;
  • R 8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, R 11 C ⁇ O, R 12 OC ⁇ O and R 13 SO 2 ;
  • each R 9 and R 10 is, independently, selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, heterocyclo, hydroxy, R 14 C ⁇ O, and R 15 C ⁇ O.
  • alkyl refers to optionally substituted straight- or branched-chain saturated hydrocarbon groups having from 1 to about 20 carbon atoms, preferably from 1 to about 7 carbon atoms.
  • lower alkyl refers to optionally substituted alkyl groups having from 1 to about 4 carbon atoms.
  • substituted alkyl refers to an alkyl group substituted by, for example, one to four substituents, such as, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyoxy, heterocylooxy, oxo, alkanoyl, aryl, aryloxy, aralkyl, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino, disubstituted amino in which the two substituents on the amino group are selected from alkyl, aryl, aralkyl, alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thiol, alkylthio, arylthio, a
  • substituents themselves are further substituted, such further substituents are selected from the group consisting of halogen, alkyl, alkoxy, aryl and aralkyl.
  • alkyl and substituted alkyl apply as well to the alkyl portion of alkoxy groups.
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • ring system refers to an optionally substituted ring system containing one to three rings and at least one carbon to carbon double bond in at least one ring.
  • exemplary ring systems include, but are not limited to, an aryl or a partially or fully unsaturated heterocyclic ring system, which may be optionally substituted.
  • aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having from about 6 to about 12 carbon atoms in the ring portion, for example, phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted.
  • aralkyl refers to an aryl group bonded to a larger entity through an alkyl group, for example, a benzyl group.
  • substituted aryl refers to an aryl group substituted by, for example, one to four substituents such as alkyl; substituted alkyl, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, aralkylamino, cycloalkylamino, heterocycloamino, alkanoylamino, thiol, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkysulfonyl, sulfonamido, aryloxy and the like.
  • the substituent may be further substituted by one or more members selected
  • cycloalkyl refers to optionally substituted saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring, which may be further fused with an unsaturated C 3 –C 7 carbocyclic ring.
  • exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, and adamantyl.
  • substituents include one or more alkyl groups as described above, or one or more of the groups described above as substituents for alkyl groups.
  • heterocycle refers to an optionally substituted, unsaturated, partially saturated, or fully saturated, aromatic or nonaromatic cyclic group, for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the nitrogen heteroatoms may also optionally be quaternized.
  • the heterocyclic group may be attached at any heteroatom or carbon atom.
  • Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4-piperidonyl, pyridyl, N-oxo-pyridyl,
  • bicyclic heterocyclic groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,1-b]pyridinyl] or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), benzisothiazolyl,
  • substituents for the terms “ring system,” “heterocycle,” “heterocyclic,” and “heterocyclo” include one or more substituent groups as described above for substituted alkyl or substituted aryl, and smaller heterocyclos, such as, epoxides, aziridines and the like.
  • alkanoyl refers to —C(O)-alkyl.
  • substituted alkanoyl refers to —C(O)-substituted alkyl.
  • heteroatoms shall include oxygen, sulfur and nitrogen.
  • the compounds represented by formula I form salts with a variety of organic and inorganic acids.
  • Such salts include those formed with hydrogen chloride, hydrogen bromide, methanesulfonic acid, hydroxyethanesulfonic acid, sulfuric acid, acetic acid, trifluoroacetic acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid and various others as are recognized by those of ordinary skill in the art of pharmaceutical compounding.
  • Such salts are formed by reacting a compound represented by formula I in an equivalent amount of the acid in a medium in which the salt precipitates or in an aqueous medium followed by evaporation.
  • inner salts can be formed and are included within the term salts as used herein.
  • a particularly preferred epothilone analog within those represented by formula I is [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-7-oxabicyclo[14.1.0]heptadecane-5,9-dione represented by formula II
  • the compounds represented by formulae I and II above are microtubule-stabilizing agents. They are thus useful in the treatment of a variety of cancers and other proliferative diseases including, but not limited to, the following:
  • carcinoma including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, including squamous cell carcinoma;
  • hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burketts lymphoma;
  • hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias and promyelocytic leukemia;
  • tumors of mesenchymal origin including fibrosarcoma and rhabdomyoscarcoma;
  • tumors including melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma;
  • tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma, and schwannomas;
  • tumors of mesenchymal origin including fibrosarcoma, rhabdomyoscaroma, and osteosarcoma;
  • tumors including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular cancer and teratocarcinoma.
  • the compounds represented by formulae I and II above will also inhibit angiogenesis, thereby affecting the growth of tumors and providing treatment of tumors and tumor-related disorders.
  • Such anti-angiogenesis properties of the compounds represented by formulae I and II will also be useful in the treatment of other conditions responsive to anti-angiogenesis agents including, but not limited to, certain forms of blindness related to retinal vascularization, arthritis, especially inflammatory arthritis, multiple sclerosis, restinosis and psoriasis.
  • Compounds represented by formulae I and II will induce or inhibit apoptosis, a physiological cell death process critical for normal development and homeostasis. Alterations of apoptotic pathways contribute to the pathogenesis of a variety of human diseases. Compounds represented by formulae I and II, as modulators of apoptosis, will be useful in the treatment of a variety of human diseases with aberrations in apoptosis including, but not limited to, cancer and precancerous lesions, immune response related diseases, viral infections, degenerative diseases of the musculoskeletal system and kidney disease.
  • each of the compounds represented by formulae I and II may also be formulated or co-administered with other therapeutic agents that are selected for their particular usefulness in administering therapies associates with the aforementioned conditions.
  • each of the compounds of formulae I and II may be formulated with agents to prevent nausea, hypersensitivity, and gastric irritation, such as anti-emetics, and H 1 and H 2 antihistamines.
  • the above therapeutic agents when employed in combination with the compound of formulae I or II, may be used in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
  • compounds of formulae I or II may be administered in combination with other anti-cancer and cytotoxic agents and treatments useful in the treatment of cancer or other proliferative diseases.
  • anti-cancer and cytotoxic drug combinations wherein the second drug chosen acts in a different manner or different phase of the cell cycle, e.g., S phase, than the present compounds of formula I and II which exert their effects at the G 2 -M phase.
  • Example classes of anti-cancer and cytotoxic agents include, but are not limited to, alkylating agents, such as nitorgen mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and triazenes; antimetabolites, such as folate antagonists, purine analogues, and pyrimidine analogues; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L-asparaginase; farnesyl-protein transferase inhibitors; hormonal agents, such as glucocorticoids, estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone anatagonists, octreotide acetate; microtubule-disruptor agents, such as ecteinascidins or their analogs and derivatives; micro
  • anti-cancer and cytotoxic agents include, but are not limited to, mechlorethamine hydrochlordie, cyclophosphamide, chlorambucil, melphalan, ifosfamide, busulfan, carmustin, lomustine, semustine, streptozocin, thiotepa, dacarbazine, methotrexate, thioguanine, mercaptopurine, fludarabine, pentastatin, cladribin, cytarabine, fluorouracil, doxorubicin hydrochloride, daunorubicin, idarubicin, bleomycin sulfate, mitomycin C, actinomycin D, safracins, saframycins, quinocarcins, discodermolides, vincristine, vinblastine, vinorelbine tartrate, etoposide, teniposide, paclitaxe
  • Preferred members of these classes include, but are not limited to, paclitaxel, cisplatin, carboplatin, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, mitomycin C, ecteinascidin 743, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podophyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, and leurosine.
  • anti-cancer and other cytotoxic agents include the following: cyclin dependent kinase inhibitors as found in WO 99/24416; and prenyl-protein transferase inhibitors as found in WO 97/30992 and WO 98/54966.
  • the compounds represented by formulae I and II may also be used to treat conditions other than cancer or other proliferative diseases.
  • Such conditions include, but are not limited to viral infections such as herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus; autoimmune diseases such as systemic lupus erythematosus, immune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases and autoimmune diabetes mellitus; neurodegenerative disorders such as Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration; AIDS; myelodysplastic syndromes; aplastic anemia; ischemic injury associated myocardial infarctions; stroke and reperfusion injury; restenosis; arrhythmia; atherosclerosis; toxin-induced or
  • the effective amount of a compound represented by formulae I and II may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a human of from about 0.05 mg/kg/day to about 200 mg/kg/day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to about 4 times per day.
  • the compounds are administered in a dosage of less than about 100 mg/kg/day, in a single dose or in about 2 to about 4 divided doses.
  • the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
  • Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats and the like, subject to the aforementioned disorders.
  • the compounds represented by formulae I and II, particularly the latter, are disadvantageous from the viewpoint of compounding a suitable formulation for administration in that they possess very low solubility in aqueous media, rapidly degrade in contact with aqueous media, are sensitive to low pH when in solution, are light sensitive, are “Class D” cytotoxic and have exceptionally poor wetting characteristics. Any one or two of these characteristics might be compensated for in compounding a pharmaceutical formulation for intravenous administration, but the combination of all of them presents a daunting challenge to the pharmaceutical compounding chemist.
  • the formulation provided in accordance with the present invention unexpectedly was found to be suitable for overcoming the disadvantageous properties of the subject epothilone analogs as noted above. Initially, because of the fact that the subject epothilone analogs are poorly soluble in aqueous media and, in fact, rapidly degrade in contact therewith, it was decided that they should be formulated in lyophilized form.
  • a suitable media to form a solution of the subject compounds for lyophilization is a mixture of tertiary-butanol and water for injection.
  • This mixture must be at least about 50% v/v, preferably from about 50% to about 80% v/v tertiary butanol to prevent degradation of the subject epothilone analogs.
  • the initial solution must be effected utilizing a mixture of at least about 60% v/v, preferably from about 60% to about 95% v/v, tertiary butanol and water.
  • both the process of forming the solution and subsequent lyophilization are to be carried out in vessels such that the epothilone analogs are protected from exposure to light. It is also beneficial to carry out the lyophilization in comparatively small batches so that the epothilone analogs are exposed to an aqueous medium for a minimum amount of time.
  • the primary drying stage of lyophilization of the solution formed as described above is carried out at temperatures from about ⁇ 10° C. to about ⁇ 40° C., preferably about ⁇ 25° C., under high vacuum, i.e., from about 50 millitorr to about 300 millitorr, preferably about 200 millitorr, for an extended period, i.e., from about 24 hours to about 96 hours, preferably about 48 hours. Lyophilization in this temperature range produces an amorphous product which is desirable for an intravenous preparation.
  • conventional procedures such as powder X-ray diffraction, can be utilized to confirm the amorphous nature of the lyophilized product.
  • the residual solvents in the product are removed by a secondary drying stage that is carried out at comparatively low temperatures, i.e., from about 10° C. to about 30° C., preferably about 25° C., under high vacuum, i.e., from about 50 millitorr to about 300 millitorr, preferably about 150 millitorr for an extended period, i.e., from about 24 hours to about 96 hours, preferably about 48 hours.
  • lyophilized epothilone analogs described herein are not enhanced by excipients commonly utilized for such purposes, such as lactose, mannitol, dextran and the like. Certain of these excipients may actually have a negative effect on the stability of the lyophilized product (lyophile).
  • excipients commonly utilized for such purposes, such as lactose, mannitol, dextran and the like. Certain of these excipients may actually have a negative effect on the stability of the lyophilized product (lyophile).
  • the epothilone analogs formulated in accordance with the present invention are lyophilized neat, i.e., without any excipient.
  • the lyophilized epothilone analogs represented by formulae I and II are reconstituted with a mixture of equal parts by volume of Dehydrated Alcohol, USP and a nonionic surfactant, preferably a polyoxyethylated castor oil surfactant available from GAF Corporation, Mount Olive, N.J., under the trademark, Cremophor EL.
  • a nonionic surfactant preferably a polyoxyethylated castor oil surfactant available from GAF Corporation, Mount Olive, N.J., under the trademark, Cremophor EL.
  • the lyophilized product and vehicle for reconstitution are packaged separately in appropriately light-protected vials. To minimize the amount of surfactant in the reconstituted solution, only a sufficient amount of the vehicle is provided to form a solution having a concentration of about 2 mg/mL to about 4 mg/mL of the epothilone analog.
  • a suitable parenteral diluent such diluents are well known to those of ordinary skill in the art. These diluents are generally available in clinical facilities. It is, however, within the scope of the present invention to package the subject epothilone analogs with a third vial containing sufficient parenteral diluent to prepare the final concentration for administration.
  • a preferred diluent is Lactated Ringer's Injection.
  • the final concentration for administration would preferably contain from about 0.1 mg/mL to about 0.9 mg/mL of the epothilone analog.
  • the final dilution of the reconstituted epothilone analog in the formulation of the invention may be carried out with other preparations having similar utility, for example, 5% Dextrose Injection, Lactated Ringer's and Dextrose Injection, Sterile Water for Injection, and the like. However, because of its narrow pH range, pH 6.0 to 7.5, Lactated Ringer's Injection is preferred. Per 100 mL, Lactated Ringer's Injection contains Sodium Chloride USP 0.6 g, Sodium Lactate 0.31 g, Potassium chloride USP 0.03 g and Calcium Chloride.2H 2 O USP 0.02 g. The osmolarity is 275 mOsmol/L, which is very close to isotonicity.
  • the constituted preparation according to the present invention i.e., the solution of the epothilone analog in the alcohol-surfactant vehicle, can be stored for up to about 24 hours before being further diluted for administration. It has been found that the incidence of allergic reactions encountered due to the presence of the surfactant in the formulation is minimized by keeping its concentration at the minimum necessary to effect solution of the epothilone analog. Further, the incidence of such reactions is about the same as has been experienced with other parenterally administered pharmaceuticals containing it, such as cyclosporine. This observed level of allergic reaction with the present formulation is significantly lower that has been experienced with certain other oncology agents, such as Paclitaxel. The final dilution is administered by intravenous infusion, typically over a period of up to an hour.
  • dissolution was completed by the addition of 600 mL of a 1:9 mixture of tertiary butanol and Water for Injection and 766 mL of a 1:1 mixture of tertiary butanol and Water for Injection which likewise had been pre-cooled to 5° C. thereby making the final solution a 1:1 mixture.
  • the dissolution was carried out under protection from light.
  • the solution formed above was promptly lyophilized in a Virtis INOTOP lyophilizer at ⁇ 16° C. under light protectant conditions over a period of 48 hours.
  • the resultant lyophilized product (lyophile) was then further dried at 15° C. under high vacuum for 48 hours. No detectable degradation of the drug was observed during these procedures.
  • the lyophile was packaged under sterile conditions into 30 mL vials, each containing 10 mg of drug and standard excess to allow for vial/needle/syringe loss.
  • the lyophile is reconstituted with 5.5 mL of a 1:1 volume mixture of Dehydrated Alcohol USP and Cremophor EL®, which typically will be supplied with the drug in a separate vial, to achieve a final drug concentration of 2 mg/mL.
  • the resultant solution is diluted to achieve a concentration of 0.2 mg/mL by the addition of 9 mL of Lactated Ringer's for Injection for each milliliter of constituted drug product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US10/051,727 2001-01-25 2002-01-17 Parenteral formulation for epothilone analogs Expired - Lifetime US7022330B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/051,727 US7022330B2 (en) 2001-01-25 2002-01-17 Parenteral formulation for epothilone analogs
US11/226,017 US20060013836A1 (en) 2001-01-25 2005-09-14 Parenteral formulation for epothilone analogs
US12/264,375 US8632788B2 (en) 2001-01-25 2008-11-04 Parenteral formulation for epothilone analogs
US14/134,172 US20140107169A1 (en) 2001-01-25 2013-12-19 Parenteral formulation for epothilone analogs
US14/686,005 US20150218179A1 (en) 2001-01-25 2015-04-14 Parenteral formulation for epothilone analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US10/051,727 US7022330B2 (en) 2001-01-25 2002-01-17 Parenteral formulation for epothilone analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/226,017 Continuation US20060013836A1 (en) 2001-01-25 2005-09-14 Parenteral formulation for epothilone analogs

Publications (2)

Publication Number Publication Date
US20020143038A1 US20020143038A1 (en) 2002-10-03
US7022330B2 true US7022330B2 (en) 2006-04-04

Family

ID=23005123

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/051,727 Expired - Lifetime US7022330B2 (en) 2001-01-25 2002-01-17 Parenteral formulation for epothilone analogs
US11/226,017 Abandoned US20060013836A1 (en) 2001-01-25 2005-09-14 Parenteral formulation for epothilone analogs
US12/264,375 Expired - Fee Related US8632788B2 (en) 2001-01-25 2008-11-04 Parenteral formulation for epothilone analogs
US14/134,172 Abandoned US20140107169A1 (en) 2001-01-25 2013-12-19 Parenteral formulation for epothilone analogs
US14/686,005 Abandoned US20150218179A1 (en) 2001-01-25 2015-04-14 Parenteral formulation for epothilone analogs

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/226,017 Abandoned US20060013836A1 (en) 2001-01-25 2005-09-14 Parenteral formulation for epothilone analogs
US12/264,375 Expired - Fee Related US8632788B2 (en) 2001-01-25 2008-11-04 Parenteral formulation for epothilone analogs
US14/134,172 Abandoned US20140107169A1 (en) 2001-01-25 2013-12-19 Parenteral formulation for epothilone analogs
US14/686,005 Abandoned US20150218179A1 (en) 2001-01-25 2015-04-14 Parenteral formulation for epothilone analogs

Country Status (24)

Country Link
US (5) US7022330B2 (ko)
EP (1) EP1353667A1 (ko)
JP (1) JP2004521122A (ko)
KR (1) KR20030071853A (ko)
CN (2) CN1489466A (ko)
AR (2) AR032408A1 (ko)
BG (1) BG108019A (ko)
BR (1) BR0206511A (ko)
CA (2) CA2434566A1 (ko)
CZ (1) CZ20032022A3 (ko)
EE (1) EE200300323A (ko)
HU (1) HUP0302567A2 (ko)
IL (1) IL156580A0 (ko)
IS (1) IS6890A (ko)
MX (1) MXPA03006485A (ko)
NO (1) NO20033342L (ko)
PE (1) PE20020733A1 (ko)
PL (1) PL367260A1 (ko)
RU (1) RU2003126171A (ko)
SI (1) SI1353668T1 (ko)
SK (1) SK8552003A3 (ko)
UY (1) UY27134A1 (ko)
WO (1) WO2002062338A1 (ko)
ZA (3) ZA200305123B (ko)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US20100015149A1 (en) * 2001-03-14 2010-01-21 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
USRE41893E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2021142202A1 (en) 2020-01-10 2021-07-15 R-Pharm Us Operating Llc Compositions of ixabepilone

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
HUP0302567A2 (hu) * 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1759115A (zh) 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050136105A1 (en) * 2003-12-22 2005-06-23 Allen Marni L. Consumer customized dosage forms
ME01881B (me) * 2004-01-22 2014-12-20 Univ Miami Topijske formulacije koenzima q10 i postupci upotrebe
RU2382647C2 (ru) * 2004-10-29 2010-02-27 Фарма Мар С.А., Сосьедад Униперсональ Композиции, содержащие эктинэсайдин и дисахарид
PE20061058A1 (es) * 2004-11-18 2006-10-13 Bristol Myers Squibb Co Composicion farmaceutica que comprende ixabepilona y proceso de preparacion
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
CN101732310B (zh) * 2006-07-12 2011-07-20 湖南迪诺制药有限公司 埃博霉素b的用途
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
CA2761717A1 (en) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
MX2015014097A (es) 2013-04-08 2016-06-07 Berg Llc Tratamiento de cancer empleando terapias combinadas de coenzima q10.
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
CN107041886A (zh) 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
JP2023508090A (ja) 2020-09-02 2023-02-28 北京華昊中天生物医薬股▲ふん▼有限公司 ウチデロンの経口固形製剤

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
WO1993010121A1 (de) 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
WO1997019086A1 (de) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilonderivate, herstellung und verwendung
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
WO1998024427A2 (en) 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970A1 (de) 1997-04-04 1998-10-08 Ludger A Dr Wessjohann Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (de) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
WO1999007692A2 (de) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
WO1999027890A2 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO1999042602A2 (en) 1998-02-19 1999-08-26 Novartis Ag Fermentative preparation process for cytostatics and crystal forms thereof
WO1999043320A1 (en) 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
WO1999054319A1 (en) 1998-04-21 1999-10-28 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
WO1999067252A2 (en) 1998-06-22 1999-12-29 Novartis Ag Epothilone derivatives and their synthesis and use
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
WO2000037473A1 (en) 1998-12-22 2000-06-29 Novartis Ag Epothilone derivatives and their use as antitumor agents
WO2000049021A2 (de) 1999-02-18 2000-08-24 Schering Aktiengesellschaft 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
WO2000066589A1 (en) 1999-04-30 2000-11-09 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20020169190A1 (en) * 2001-01-25 2002-11-14 Rebanta Bandyopadhyay Methods of administering epothilone analogs for the treatment of cancer
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6576651B2 (en) * 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US6650599B2 (en) 1998-01-23 2003-11-18 Sanyo Electric Co., Ltd. Method and apparatus for determining power level of laser beam in magneto-optical recording device
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6689802B2 (en) * 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3486283B2 (ja) * 1996-01-31 2004-01-13 三菱重工業株式会社 重質油の脱水方法
ATE215820T1 (de) * 1997-10-08 2002-04-15 Sepracor Inc Dosierungsform zur verabreichung von aerosolen
US6683100B2 (en) * 1999-01-19 2004-01-27 Novartis Ag Organic compounds
AU772750C (en) * 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US6364749B1 (en) * 1999-09-02 2002-04-02 Micron Technology, Inc. CMP polishing pad with hydrophilic surfaces for enhanced wetting
US20030017169A1 (en) * 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
HUP0302567A2 (hu) * 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra

Patent Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
WO1993010121A1 (de) 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel
DE4138042A1 (de) 1991-11-19 1993-05-27 Biotechnolog Forschung Gmbh Epothilone, deren herstellungsverfahren sowie sie enthaltende mittel
WO1997019086A1 (de) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilonderivate, herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
EP0941227A1 (de) 1996-11-18 1999-09-15 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
WO1998024427A2 (en) 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
ATE221888T1 (de) 1997-02-25 2002-08-15 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970A1 (de) 1997-04-04 1998-10-08 Ludger A Dr Wessjohann Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
EP0879605A2 (de) 1997-05-15 1998-11-25 Hoechst Aktiengesellschaft Glykosyl-prodroge konjugat mit erhörter verträglichkeit
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (de) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
WO1999007692A2 (de) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
WO1999027890A2 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6650599B2 (en) 1998-01-23 2003-11-18 Sanyo Electric Co., Ltd. Method and apparatus for determining power level of laser beam in magneto-optical recording device
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO1999042602A2 (en) 1998-02-19 1999-08-26 Novartis Ag Fermentative preparation process for cytostatics and crystal forms thereof
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO1999043320A1 (en) 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO1999054319A1 (en) 1998-04-21 1999-10-28 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO1999067252A2 (en) 1998-06-22 1999-12-29 Novartis Ag Epothilone derivatives and their synthesis and use
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
WO2000037473A1 (en) 1998-12-22 2000-06-29 Novartis Ag Epothilone derivatives and their use as antitumor agents
US6387927B1 (en) 1998-12-22 2002-05-14 Novatis Ag Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
WO2000049021A2 (de) 1999-02-18 2000-08-24 Schering Aktiengesellschaft 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
WO2000066589A1 (en) 1999-04-30 2000-11-09 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US6689802B2 (en) * 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US20020169190A1 (en) * 2001-01-25 2002-11-14 Rebanta Bandyopadhyay Methods of administering epothilone analogs for the treatment of cancer
US6576651B2 (en) * 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US6670384B2 (en) 2001-01-25 2003-12-30 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives

Non-Patent Citations (58)

* Cited by examiner, † Cited by third party
Title
Altmann, K.H., et al., "Epothilones and Related Structures-A New Class of Microtubule Inhibitors With Patent In Vivo Antitumor Activity," Biochim. Biophys Acta, 1470 (2000).
Balog, A., et al., "Total Synthesis of (-)-Epothilone A", Angew. Chem. Int. Ed. Engl., vol. 35, No. 23/24, 2801-2803 (1996).
Bertinato, P., et al., "Studies Toward a Synthesis of Epothilone A: Stereocontrolled Assembly of the Acyl Region and Models for Macrocyclization", J. Org. Chem., vol. 61, No. 23, 8000-8001 (1996).
Bertini, F., et al., "Alkenes from Epoxides by Reductive Elimination with Magnesium Bromide-Magnesium Amalgam", Chem. Commun. , 144 (1970).
Bollag, D., "Epothilones: Novel Microtuble-Stabilising Agents", Expert Opin. Invest. Drugs, vol. 6, No. 7, 867-873 (1997).
Bollag, D., et al., "Epothilone, A New Structural Class Microtuble Stabilizer", Abstract, Proc. Am. Assoc. Cancer Res., vol. 36, 86 Meet. 454 (1995).
Bollag, D.M., et al., "Epothilones, A New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action", Cancer Res. 55, No. 11, 2325-2333 (1995).
Chemical & Engineering News, "Epothilone Epiphany: Total Syntheses", vol. 74, No. 52, 24-26 (1996).
Chemical & Engineering News, "First Total Synthesis of Epothilone B", vol. 75, No. 13, 23 (1997).
Chemical & Engineering News, "Solid-Phase Epothilone Synthesis Used to Create Analog Library", vol. 75, No. 20, 33 (1997).
Claus, E., et al., "Synthesis of the C1-C9 Segment of Epothilons", Tetrahedron Lett., vol. 38, No. 8, 1359-1362 (1997).
De Brabander, J., et al., "Towards a Synthesis of Epothilone A: Rapid Assembly of the C1-C6 and C7-C12 Fragments", Synlett, vol. 7, 824-826 (1997).
Fujisawa, T., et al., "Deoxygenation of Epoxides to Olefins with FeCl<SUB>3</SUB>-n-BuLi System", Chem. Lett., 883-886 (1974).
Fujiwara, Y., et al., "Reductive Coupling of Carbonyl Compounds to Olefins by Tungsten Hexachloride-Lithium Aluminum Hydride and Some Tungsten and Molybdenum Carbonyls", J. Org. Chem., vol. 43, No. 12, 2477-2479 (1978).
Gabriel, T. and Wessjohann, L., "The Chromium-Reformatsky Reaction: Asymmetric Synthesis of the Aldol Fragment of the Cytotoxic Epothilons from 3-(2-Bromoacyl)-2-Oxazolidinones", Tetrahedron Lett., vol. 38, No. 8, 1363-1366 (1997).
Gerth, K., et al., "Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangiusm cellulosum (Myxobacteria) Production Physico-chemical and Biological Properties", J. Antibiotics, vol. 46, No. 6, 560-563 (1996).
Gladysz, J. A., et al., "Deoxygenation of Epoxides by Metal Atom Cocondensation", J. Org. Chem., vol. 41, No. 22, 3647-3648 (1976).
Hofle, G., et al., "Epothilone A and B-Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution", Angew. Chem. Int. Ed. Engl., vol. 35, No. 13/14, 1567-1569 (1996).
Hofle, G., et al., "N-Oxidation of Epothilone A-C and O-Acyl Rearrangement to C-19 and C-21-Substituted Epothilones", Angew. Chem. Int. Ed., vol. 38, No. 13/14, 1971-1974 (1999).
Inokuchi, T., et al., "Opening of Epoxides to Olefins or Halohydrins with Vanadium(II)-Tetrahydrofuran or Vanadium(III)-Tetrahydrofuran Complexes", Synlett, No. 6, 510-512 (1992).
Kowalski. R. J., et al., "Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol(R))" J. Biol. Chem., vol 272, No. 4, 2534-2541 (1997).
Kupchan, S. M., et al., "Reductive Elimination of Epoxides to Olefins with Zinc-Copper Couple", J. Org. Chem., vol. 36, No. 9, 1187-1190 (1971).
Marshall, A., "Total Synthesis of Epothilone", Nature Biotechnology, vol. 15, No. 3, 205 (1997).
Martin, M. G., et al., "Epoxides as Alkene Protecting Groups. A Mild and Efficient Deoxygenation", Tetrahedron Letters, vol. 25, No. 3, 251-254 (1984).
McMurry, J. E., et al., "Reduction of Epoxides to Olefins with Low Valent Titanium", J. Org. Chem., vol. 40, No. 17, 2555-2556 (1975).
McMurry, J. E., et al., "Some Deoxygenation Reactions with Low-Valent Titanium (TiCl<SUB>3</SUB>/LiAIH<SUB>4</SUB>)", J. Org. Chem., vol. 43, No. 17, 3249-3254 (1978).
Meng, D., et al., "Remote Effects in Macrolide Formation Through Ring-Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners", J. Am. Chem. Soc., vol. 119, No. 11, 2733-2734 (1997).
Meng, D., et al., "Studies Toward a Synthesis of Epothilone A: Use of Hydropyran Templates for the Management of Acyclic Stereochemical Relationships", J. Org. Chem., vol. 61, No. 23, 7998-7999 (1996).
Meng, D., et al., "Total Syntheses of Epothilones A and B", J. Am. Chem. Soc., vol. 119, No. 42, 10073-10092 (1997).
Mensching, S. and Kalesse, M., "Generation of Thiazoles by Column Dehydrogenation of Thiazolidines with MnO<SUB>2</SUB>", J. Prakt. Chem., vol. 339, No. 1, 96-97 (1997).
Mulzer, J. and Mantoulidis, A., "Synthesis of the C(1)-C(9) Segment of the Cytotoxic Macrolides Epothilon A and B", Tetrahedron Lett., vol. 37, No. 51, 9179-9182 (1996).
Nicolaou et al., "Chemical Biology of Epothilones", Angew. Chem. Int. Ed., 37, 2014-2045 (1988).
Nicolaou et al., "Total Synthesis of Epothilone E and Analogs with Modified Side Chains Through The Stille Coupling Reaction", Angew. Chem. Int. Ed. 37, 84-87 (1998).
Nicolaou et al., "Total Synthesis of Oxazole- and Cyclopropane-Containing Epothilone B Analogues by the Macrolactonization Approach", Chemistry, European Journal, vol. 3, No. 12, 1971-1986 (1997).
Nicolaou, K. C., et al., "An Approach to Epothilones Based on Olefin Metathesis", Angew. Chem. Int. Ed. Engl., vol. 35, No. 20, 2399-2401 (1996).
Nicolaou, K. C., et al., "Designed Epothilones: Combinatorial Synthesis, Tubulin Assembly Properties, and Cytotoxic Action against Taxol-Resistant Tumor Cells", Angew. Chem. Int. Ed. Engl., vol. 36, No. 19, 2097-2103 (1997).
Nicolaou, K. C., et al., "Synthesis and Biological Properties of C12, 13-Cyclopropylepothilone A and Related Epothilones", Chemistry & Biology, vol. 5, No. 7, 365-372 (1998).
Nicolaou, K. C., et al., "Synthesis of Epothilones A and B in Solid and Solution Phase" (Correction to Nature 387, 268-272 (1997)), Nature, 390, 100 (1997).
Nicolaou, K. C., et al., "Synthesis of Epothilones A and B in Solid and Solution Phase", Nature, vol. 387, 268-272 (1997).
Nicolaou, K. C., et al., "Total Syntheses of Epothilones A and B via a Macrolactonization-Based Strategy", J. Am. Chem. Soc., vol. 119, No. 34, 7974-7991 (1997).
Nicolaou, K. C., et al., "Total Synthesis of Epothilone A: The Macrolactonization Approach", Angew. Chem. Int. Ed. Engl., vol. 36, No. 5, 525-527 (1997).
Nicolaou, K., et al., "Chemistry, Biology and Medicine of Selected Tubulin Polymerizing Agents", Pure Appl. Chem., vol. 71, No. 6, 989-997 (1999).
Nicolaou, K., et al., "Total Synthesis of Epothilone E and Related Side-chain Modified Analogues Via a Stille Coupling Based Strategy", Bioorg. Med. Chem., vol. 7, No. 5; 665-697 (1999).
Nicolaou, K.C., et al., "The Olefin Metathesis Approach to Epothilone A and Its Analogues", J. Am. Chem. Soc., vol. 119, No. 34, 7960-7973 (1997).
Raucher, S., et al., "Total Synthesis of (+)-Dihydrocostunolide via Tandem Cope-Claisen Rearrangement", J. Org. Chem., vol. 51, No. 26, 5503-5505 (1986).
Sato, M, et al., "Reduction of Organic Compounds with Low-Valent Niobium (NbCI<SUB>5</SUB>/NaAIH<SUB>4</SUB>)", Chem. Letters, 157-160 (1982).
Schinzer, D., et al., "Studies Towards the Total Synthesis of Epothilones: Asymmetric Synthesis of the Key Fragments", Chem. Eur. J., vol. 2, No. 22, 1477-1482 (1996).
Schinzer, D., et al., "Syntheses of (-)-Epothilone A", Chem. Eur. J., vol. 5, No. 9, 2483-2491 (1999).
Schinzer, D., et al., "Syntheses of (-)-Epothilone B", Chem. Eur. J., vol. 5, No. 9, 2492-2500 (1999).
Schinzer, D., et al., "Total Synthesis of (-)-Epothilone A", Angew. Chem. Int. Ed. Engl., vol. 36, No. 5, 523-524 (1997).
Schobert, R., et al., "Reduction and Isomerization of Oxiranes and alpha-Diazoketones by Various Early Transition Metallocenes", Synlett, vol. 8, 465-466 (1990).
Sharpless, K. B., et al., "Lower Valent Tungsten Halides. A New Class of Reagents for Deoxygenation of Organic Molecules", J. Amer. Chem. Soc., vol. 94, No. 18, 6538-6540 (1972).
Su, D.-S., et al., "Structure-Activity Relationships of the Epothilones and the First In Vivo Comparison with Paclitaxel", Angew. Chem. Int. Ed. Engl., vol. 36, No. 19, 2093-2096 (1997).
Su, D.-S., et al., "Total Synthesis of (-)-Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure-Activity Relationships of the Epothilones", Angew. Chem. Int. Ed. Engl., vol. 36, No. 7, 757-759 (1997).
Taylor, R. and Haley, J., "Towards the Synthesis of Epothilone A: Enantioselective Preparation of the Thiazole Sidechain and Macrocyclic Ring Closure", Tetrahedron Lett., vol. 38, No. 12, 2061-2064 (1997).
Victory, S. F., et al., "Relative Stereochemistry and Solution Conformation of the Novel Paclitaxel-Like Antimitotic Agent Epothilone A", Bioorg. Med. Chem. Letts., vol. 6., No. 7, 893-898 (1996).
Winkler, J. D., et al., "A Model For the Taxol (Paclitaxel)/Epothilone Pharmacophore", Bioorg. Med. Chem. Letts., vol. 6, No. 24, 2963-2966 (1996).
Yang, Z., et al., "Total Synthesis of Epothilone A: The Olefin Metathesis Approach", Angew. Chem. Int. Ed. Engl., vol. 36, No. 1/2, 166-168 (1997).

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41893E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
USRE41895E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
USRE41911E1 (en) 1997-07-08 2010-11-02 Bristol-Myers Squibb Company Epothilone derivatives
US20100015149A1 (en) * 2001-03-14 2010-01-21 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US8598215B2 (en) 2001-03-14 2013-12-03 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
WO2007140299A3 (en) * 2006-05-25 2008-07-03 Bristol Myers Squibb Co Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US9441000B2 (en) 2011-06-06 2016-09-13 Chevron Philips Chemical Company, Lp Use of metallocene compounds for cancer treatment
WO2021142202A1 (en) 2020-01-10 2021-07-15 R-Pharm Us Operating Llc Compositions of ixabepilone

Also Published As

Publication number Publication date
US20140107169A1 (en) 2014-04-17
EP1353667A1 (en) 2003-10-22
AR098109A2 (es) 2016-05-04
UY27134A1 (es) 2002-08-30
ZA200305123B (en) 2004-10-01
CZ20032022A3 (cs) 2004-04-14
BR0206511A (pt) 2003-10-21
CA2681962A1 (en) 2002-08-01
ZA200305536B (en) 2004-09-06
US8632788B2 (en) 2014-01-21
PL367260A1 (en) 2005-02-21
PE20020733A1 (es) 2002-08-11
CN101112373A (zh) 2008-01-30
KR20030071853A (ko) 2003-09-06
US20060013836A1 (en) 2006-01-19
JP2004521122A (ja) 2004-07-15
SI1353668T1 (sl) 2008-08-31
US20020143038A1 (en) 2002-10-03
BG108019A (en) 2004-09-30
AR032408A1 (es) 2003-11-05
HUP0302567A2 (hu) 2003-12-29
RU2003126171A (ru) 2005-02-27
CA2681962C (en) 2012-06-12
WO2002062338A1 (en) 2002-08-15
MXPA03006485A (es) 2003-09-22
ZA200305126B (en) 2004-10-01
NO20033342L (no) 2003-09-22
EE200300323A (et) 2003-10-15
IL156580A0 (en) 2004-01-04
CA2434566A1 (en) 2002-08-15
CN1489466A (zh) 2004-04-14
US20090069393A1 (en) 2009-03-12
CN101112373B (zh) 2012-06-20
SK8552003A3 (en) 2004-06-08
IS6890A (is) 2003-07-24
US20150218179A1 (en) 2015-08-06
NO20033342D0 (no) 2003-07-24

Similar Documents

Publication Publication Date Title
US7022330B2 (en) Parenteral formulation for epothilone analogs
US6670384B2 (en) Methods of administering epothilone analogs for the treatment of cancer
US7053069B2 (en) Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US8871227B2 (en) Process and formulation containing epothilones and analogs thereof
AU2002245296B2 (en) Methods of administering epothilone analogs for the treatment of cancer
AU2002245296A1 (en) Methods of administering epothilone analogs for the treatment of cancer
US20090004277A1 (en) Nanoparticle dispersion containing lactam compound
AU2002243548A1 (en) Parenteral formulation containing epothilone analogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BANDYOPADHYAY, REBENTA;MALLOY, TIMOTHY M.;PANAGGIO, ANDREA;AND OTHERS;REEL/FRAME:012593/0470;SIGNING DATES FROM 20020410 TO 20020412

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: R-PHARM US OPERATING LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRISTOL-MYERS SQUIBB COMPANY;REEL/FRAME:036585/0956

Effective date: 20150701

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553)

Year of fee payment: 12